HomeCompareTKBIF vs VIG

TKBIF vs VIG: Dividend Comparison 2026

TKBIF yields 1.58% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VIG wins by $10.4K in total portfolio value
10 years
TKBIF
TKBIF
● Live price
1.58%
Share price
$7.30
Annual div
$0.12
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.0K
Annual income
$174.62
Full TKBIF calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — TKBIF vs VIG

📍 VIG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTKBIFVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TKBIF + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TKBIF pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TKBIF
Annual income on $10K today (after 15% tax)
$134.02/yr
After 10yr DRIP, annual income (after tax)
$148.43/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, VIG beats the other by $3.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TKBIF + VIG for your $10,000?

TKBIF: 50%VIG: 50%
100% VIG50/50100% TKBIF
Portfolio after 10yr
$27.2K
Annual income
$176.89/yr
Blended yield
0.65%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TKBIF buys
0
VIG buys
0
No recent congressional trades found for TKBIF or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTKBIFVIG
Forward yield1.58%1.64%
Annual dividend / share$0.12$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$22.0K$32.4K
Annual income after 10y$174.62$179.15
Total dividends collected$1.7K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: TKBIF vs VIG ($10,000, DRIP)

YearTKBIF PortfolioTKBIF Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$10,858$157.67$11,304$163.92$446.00VIG
2$11,778$159.99$12,759$166.33$981.00VIG
3$12,764$162.20$14,382$168.52$1.6KVIG
4$13,822$164.29$16,192$170.52$2.4KVIG
5$14,956$166.26$18,210$172.34$3.3KVIG
6$16,171$168.13$20,460$173.98$4.3KVIG
7$17,473$169.90$22,968$175.48$5.5KVIG
8$18,868$171.57$25,763$176.83$6.9KVIG
9$20,361$173.14$28,878$178.05$8.5KVIG
10$21,961$174.62$32,350$179.15$10.4KVIG

TKBIF vs VIG: Complete Analysis 2026

TKBIFStock

Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing. In addition, the company is involved in developing platform technology for biologics development in areas, such as gene therapy. The company was incorporated in 2002 and is based in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

Full TKBIF Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this TKBIF vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TKBIF vs SCHDTKBIF vs JEPITKBIF vs OTKBIF vs KOTKBIF vs MAINTKBIF vs DGROTKBIF vs NOBLTKBIF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.